Men syndrome
Reading File
MEN (Multiple Endocrine Neoplasia) syndromes are rare autosomal dominant disorders causing tumors in multiple endocrine glands. There are three main types: MEN1 (parathyroid, pituitary, pancreas), MEN2A (medullary thyroid carcinoma, pheochromocytoma, parathyroid), and MEN2B (medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas).
Searching sources...
Finding Sources
Searching PubMed
"multiple endocrine neoplasia" MEN syndrome
Reading File
Reading File
Reading File
Reading File
Here is a thorough overview of Multiple Endocrine Neoplasia (MEN) syndromes based on authoritative medical textbooks:
Multiple Endocrine Neoplasia (MEN) Syndromes
MEN syndromes are a group of autosomal dominant inherited disorders causing proliferative lesions (hyperplasias, adenomas, and carcinomas) in multiple endocrine organs. They share several features that distinguish them from sporadic endocrine tumors:
- Tumors occur at a younger age
- They arise in multiple organs, either simultaneously (synchronously) or at different times (metachronously)
- Within a single organ, tumors are often multifocal
- They are typically preceded by an asymptomatic hyperplastic stage
- They are generally more aggressive and have higher recurrence rates
MEN-1 (Werner Syndrome)
Prevalence: ~2 per 100,000
Gene: MEN1 tumor suppressor gene - encodes a protein called menin, a component of transcription factor complexes. Loss of menin function causes uncontrolled transcriptional activity and neoplasia.
Classic triad - the "3 Ps":
| Organ | Manifestation | Details |
|---|---|---|
| Parathyroid | Primary hyperparathyroidism | Most common manifestation (80%-95%); presents as hyperplasias and adenomas; nearly universal by age 40-50 |
| Pancreas | Pancreatic endocrine tumors | Leading cause of death in MEN-1; often functional; Zollinger-Ellison syndrome (gastrinoma) and hypoglycemia (insulinoma) are most common |
| Pituitary | Anterior pituitary adenoma | Most commonly prolactinoma (macroadenoma); acromegaly can occur with somatotropin-secreting tumors |
Additional features: Duodenal gastrinomas (most common site for gastrinomas in MEN-1), carcinoid tumors, thyroid and adrenocortical adenomas, and lipomas are more frequent than in the general population.
Key note: The duodenum is the most common site of gastrinomas in MEN-1, not the pancreas.
MEN-2A (Sipple Syndrome)
Gene: Germline gain-of-function mutations in the RET proto-oncogene (encodes a receptor tyrosine kinase that binds glial-derived neurotrophic factor)
| Organ | Manifestation | Frequency |
|---|---|---|
| Thyroid (C-cells) | Medullary thyroid carcinoma (MTC) | ~100% of untreated patients; multifocal; often in first two decades of life |
| Adrenal medulla | Pheochromocytoma | 40%-50%; often bilateral; may be extra-adrenal; <10% malignant |
| Parathyroid | Hyperplasia/hypercalcemia | 10%-20%; renal stones may occur |
Variant - Familial Medullary Thyroid Carcinoma (FMTC): Germline RET mutations with isolated MTC, without pheochromocytoma or hyperparathyroidism; tends to be less aggressive and presents at an older age.
MEN-2B (also called MEN-3)
Gene: A single missense point mutation in RET (distinct from MEN-2A mutations), affecting the tyrosine kinase domain, causing constitutive RET activation.
| Feature | Details |
|---|---|
| Medullary thyroid carcinoma | Present; multifocal and more aggressive than in MEN-2A |
| Pheochromocytoma | Present |
| Primary hyperparathyroidism | Absent (key distinguishing feature from MEN-2A) |
| Mucosal/cutaneous neuromas | Ganglioneuromas of lips, tongue, GI tract, skin, eyes, respiratory tract |
| Marfanoid habitus | Long axial skeletal features, hyperextensible joints |
MEN-4
A newer entity that phenocopies MEN-1 clinically, but caused by germline inactivating mutations in CDKN1B, leading to reduced levels of the cell-cycle checkpoint protein p27 (a cyclin-dependent kinase inhibitor).
MEN-5 (Newly Described)
Caused by germline mutations in the MAX tumor suppressor gene. Patients often develop bilateral pheochromocytomas and other tumors. Unlike MEN-2, medullary thyroid carcinoma and C-cell hyperplasia are not seen.
Genetics & Screening Summary
| Syndrome | Gene | Mutation Type | Key Organ |
|---|---|---|---|
| MEN-1 | MEN1 | Loss-of-function (TSG) | Parathyroid > Pancreas > Pituitary |
| MEN-2A | RET | Gain-of-function | Thyroid (MTC), Adrenal, Parathyroid |
| MEN-2B / MEN-3 | RET | Gain-of-function (single missense) | Thyroid (MTC), Adrenal, Neuromas |
| MEN-4 | CDKN1B | Loss-of-function (TSG) | Mimics MEN-1 |
| MEN-5 | MAX | Loss-of-function (TSG) | Bilateral Pheochromocytoma |
Important clinical implication for MEN-2: All patients with medullary thyroid carcinoma - including apparently sporadic cases - should undergo germline RET mutation testing. Carriers are advised to have prophylactic thyroidectomy to prevent the inevitable development of medullary carcinomas (since MTC occurs in virtually 100% of untreated individuals).
In contrast to MEN-1, the benefit of early diagnosis via genetic screening is clearly established in MEN-2 given the life-threatening, preventable nature of MTC.
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease
Can you create a table containing etiopathogenesis, clinical features, management , complications and any other extra relevant points for all types of men syndrome. Make a single table
Searching sources...
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive data from multiple authoritative surgical and pathology textbooks. Here is the complete single table:
MEN Syndromes - Comprehensive Comparison Table
| Feature | MEN-1 (Werner Syndrome) | MEN-2A (Sipple Syndrome) | MEN-2B (MEN-3) | MEN-4 |
|---|---|---|---|---|
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant; ~50% arise as de novo mutations | Autosomal dominant |
| Gene Mutated | MEN1 (tumor suppressor gene) on chromosome 11q13 | RET proto-oncogene on chromosome 10q11 | RET proto-oncogene on chromosome 10q11 | CDKN1B (tumor suppressor gene) |
| Protein Affected | Menin - component of transcription factor complexes; loss leads to uncontrolled transcription | RET receptor tyrosine kinase (binds GDNF); gain-of-function = constitutive activation | RET receptor tyrosine kinase - single missense point mutation in tyrosine kinase domain | p27 (Kip1) - cyclin-dependent kinase inhibitor; arrests cell cycle at G1/S; binds CDK4 |
| Type of Mutation | Loss-of-function (TSG - two-hit model: inherited first hit + somatic second hit) | Gain-of-function (missense mutations, mainly exons 10/11) | Gain-of-function (single amino acid substitution, codon 918 of tyrosine kinase domain) | Loss-of-function (TSG - inactivating mutation) |
| Mechanism | Loss of menin disrupts histone methylation and transcriptional regulation, promoting neoplasia in susceptible tissues | Constitutive RET activation drives unchecked growth/differentiation signaling in C-cells and chromaffin cells | Constitutive RET activation (distinct from MEN-2A mutations) - more potent activation, explaining greater aggressiveness | Loss of p27 allows unphosphorylated retinoblastoma protein (Rb) to be phosphorylated by CDK4/cyclin complexes, allowing unchecked cell cycle progression |
| Organs Involved | 3 Ps: Parathyroid, Pancreas (islet cells), Pituitary | Thyroid (C-cells), Adrenal medulla, Parathyroid | Thyroid (C-cells), Adrenal medulla, Peripheral/mucosal nervous system | Parathyroid, Pituitary, Pancreas (NETs) - mimics MEN-1 |
| Typical Age of Onset | 3rd-4th decade; complete penetrance by 40-50 yrs | 2nd-3rd decade | Earlier than MEN-2A, often in childhood/infancy | 5th decade (mean); generally presents later and milder than MEN-1 |
| Parathyroid | Primary hyperparathyroidism in 80%-95% (most common and often first manifestation); multiglandular hyperplasia and adenomas; usually symptomatic via urinary tract (renal stones) rather than bone disease | Parathyroid hyperplasia in 10%-20%; often multiglandular chief cell hyperplasia; usually asymptomatic; nephrolithiasis occasionally | Absent (key distinguishing feature from MEN-2A) | PHPT in >90% (first manifestation); diffuse parathyroid hyperplasia |
| Pancreatic/GI Tumors | Leading cause of death in MEN-1; multifocal islet cell NETs throughout pancreas; often functional: - Gastrinoma (most common functional tumor; usually in duodenal wall submucosa) - Insulinoma (2nd most common) - VIPoma, glucagonoma (less common) - Pancreatic polypeptidoma (most common secreted product overall) | Not a feature | Not a feature | NETs in ~20% (less frequent than MEN-1); gastrinoma is most common functional NET type |
| Thyroid | Not a primary feature (thyroid adenomas occur at slightly increased frequency) | Medullary thyroid carcinoma (MTC) in virtually 100% of untreated patients; multifocal; bilateral; C-cell hyperplasia precedes; arises 1st-2nd decade; relatively indolent course | MTC in virtually 100%; multifocal, bilateral; more aggressive than MEN-2A; arises even earlier (infancy/childhood) | Not a feature |
| Pituitary | Pituitary adenomas in 15%-50%; most commonly prolactinoma (macroadenoma); acromegaly from GH-secreting tumor; rarely ACTH-secreting (Cushing's) | Not a feature | Not a feature | Pituitary adenomas in ~40%; ACTH-secreting adenoma more common (40% of pituitary tumors vs 5% in MEN-1); prolactinoma also occurs |
| Adrenal | Adrenocortical adenomas (benign, non-functional; management conservative) | Pheochromocytoma in 40%-50%; usually bilateral (~80%); benign (<10% malignant); adrenal medullary hyperplasia precedes | Pheochromocytoma; similar frequency to MEN-2A; bilateral; benign | Not a primary feature |
| Extra-endocrine Features | Lipomas (visceral, pleural, retroperitoneal); carcinoid tumors (thymic, bronchial, gastric); cutaneous angiofibromas; collagenomas | None beyond endocrine organs | Mucosal/cutaneous neuromas (tongue, lips, eyelids, pharynx); marfanoid habitus (long axial bones, hyperextensible joints, pectus excavatum, kyphosis, pes planus, scoliosis, congenital hip dislocation); ganglioneuromatosis of GI tract (submucosal/myenteric plexus); thick lips; hypertrophied corneal nerves (slit-lamp); constipation/megacolon picture; diffuse autonomic hypertrophy | None beyond endocrine organs |
| Key Clinical Presentations | - Hypercalcemia (fatigue, polyuria, renal stones) - Peptic ulcer disease / ZES (recurrent, severe) - Secretory diarrhea - Hypoglycemia (sweating, confusion, syncope) - Galactorrhea/amenorrhea (prolactinoma) - Acromegaly | - Neck mass (MTC) - Hoarseness, dysphagia - Hypertension (episodic or sustained) - Pounding headaches, diaphoresis, palpitations (pheo) - Renal stones (hyperparathyroidism) - Diarrhea (calcitonin excess) | - Neck mass (MTC) - Mucosal neuromas on tongue/lips (often first sign in newborns) - Marfanoid body habitus - Pheochromocytoma symptoms - GI symptoms (constipation, dysmotility) | - Hypercalcemia (renal stones, fatigue) - Peptic ulcer / secretory diarrhea (gastrinoma) - Cushing's disease or acromegaly (pituitary) |
| Biochemical Markers | - Elevated PTH + hypercalcemia - Elevated fasting serum gastrin (>1000 pg/mL in ZES); secretin stimulation test - Fasting hypoglycemia + elevated insulin (insulinoma) - Elevated prolactin or IGF-1 | - Elevated calcitonin (basal and pentagastrin/calcium-stimulated) - Elevated plasma metanephrines (pheochromocytoma) - PTH + calcium (parathyroid) | - Elevated calcitonin - Elevated plasma metanephrines - RET mutation on genetic testing | - PTH + calcium - Fasting gastrin - Prolactin, IGF-1, ACTH (pituitary screen) |
| Management - Parathyroid | Subtotal parathyroidectomy (preferred) or total parathyroidectomy with autograft; no truly curative option due to multifocal nature and metachronous recurrence | Total parathyroidectomy + heterotopic autotransplantation in hypercalcemic patients; in normocalcemic patients found with enlarged glands during thyroidectomy - remove only enlarged glands | Not applicable (no hyperparathyroidism) | Follow MEN-1 guidelines; parathyroidectomy for symptomatic hypercalcemia |
| Management - Pancreas / GI | - Gastrinoma: PPIs/H2 blockers (often high dose); surgical resection if isolated; nonsurgical approach generally preferred in MEN-1 due to multifocality - Insulinoma: surgical resection (enucleation or distal pancreatectomy); preop localization by CT + arterial calcium stimulation test - Nonfunctional NETs: watchful waiting if small; surgery for >2 cm or growing lesions - Somatostatin receptor scintigraphy for staging | Not applicable | Not applicable | Same principles as MEN-1; management guidelines not yet standardized (MEN-1 guidelines adopted) |
| Management - Thyroid (MTC) | Not applicable (no MTC) | - Prophylactic thyroidectomy for all RET mutation carriers (timing based on mutation risk category) - Total thyroidectomy + central lymph node dissection - Postop: lifelong calcitonin monitoring - Vandetanib or cabozantinib for metastatic/unresectable MTC - Surgical reoperation for persistently elevated calcitonin | - Urgent prophylactic thyroidectomy in infancy (before age 6 months) due to aggressiveness - Total thyroidectomy + central neck dissection - Postoperative calcitonin monitoring | Not applicable |
| Management - Pheochromocytoma | Not applicable | - Pheochromocytoma MUST be resected before thyroidectomy - Alpha-blockade (phenoxybenzamine) preoperatively - Laparoscopic adrenalectomy preferred; bilateral adrenalectomy for bilateral disease - Unilateral disease: remove affected gland only (avoids Addisonian crisis); ~30% develop contralateral tumor | Same as MEN-2A; urgent management given aggressiveness | Not applicable |
| Management - Pituitary | Prolactinoma: dopamine agonists (cabergoline, bromocriptine); surgery (transsphenoidal) if drug-resistant; GH-secreting: surgery ± octreotide/lanreotide | Not applicable | Not applicable | Similar to MEN-1 pituitary management |
| Screening / Surveillance | - Annual biochemistry: calcium, PTH, fasting gastrin, insulin, prolactin, IGF-1 - Imaging: MRI pituitary, CT/MRI abdomen - Genetic testing of all first-degree relatives - Start screening from age 5-10 yrs in carriers | - Germline RET testing in all patients with MTC (including sporadic cases) - Annual calcitonin + plasma metanephrines in carriers - Prophylactic thyroidectomy timing by mutation risk category - 6-monthly or annual plasma metanephrines post-adrenalectomy | - RET genetic testing - Early thyroidectomy before 6 months of age - Annual plasma metanephrines - Slit-lamp for corneal nerve hypertrophy | - If MEN-1 mutation negative, do next-generation sequencing for CDKN1B - Follow modified MEN-1 surveillance protocols - No consensus guidelines yet |
| Complications | - Metastatic pancreatic NETs (leading cause of death ~45% of MEN-1 deaths) - Malignant carcinoid tumors - Nephrolithiasis / nephrocalcinosis from hypercalcemia - Peptic ulcer complications (perforation, bleeding) - Hypoglycemic coma (insulinoma) - Hypopituitarism / visual field defects (macroadenoma) | - Metastatic MTC (main determinant of prognosis; indolent in MEN-2A) - Hypertensive crisis from pheochromocytoma (fatal if unrecognized pre-operatively) - Renal stones from hyperparathyroidism - Addisonian crisis post bilateral adrenalectomy | - Most aggressive form of MEN - Metastatic MTC (more aggressive than MEN-2A; early death if not treated in infancy) - Hypertensive crisis from pheochromocytoma - GI dysmotility / pseudo-obstruction (ganglioneuromatosis) - Skeletal deformity complications | - Metastatic NETs - Hypercalcemia complications - Cushing's disease complications (if ACTH adenoma) |
| Prognosis | Determined by malignant NETs and carcinoid tumors; hyperparathyroidism itself rarely fatal; ~45% of deaths MEN-1 related; islet cell malignancy is leading killer | MTC course is often indolent; survival can be prolonged even with metastatic disease; pheochromocytoma rarely malignant (<10%) | Worst prognosis of all MEN types; MTC arises earlier and is more aggressive; patients may succumb at a young age; kindred size typically small due to early deaths | Generally favorable; mild and late presentation; prognosis data limited (~80 cases reported in literature) |
| Key Distinguishing Points | - "3 Ps" mnemonic - Duodenum is #1 site for gastrinomas (not pancreas) - TSG mutation (loss-of-function) - Pancreatic NETs are the killer | - Pheo must be ruled out BEFORE thyroid surgery - Parathyroid involved (unlike MEN-2B) - RET gain-of-function | - No hyperparathyroidism (unlike MEN-2A) - Mucosal neuromas + marfanoid habitus are pathognomonic - Most aggressive MEN - Often new (de novo) mutation - Also called MEN-3 | - Phenocopies MEN-1 clinically - Older age at presentation - ACTH adenoma more common than prolactinoma (vs MEN-1) - NETs less frequent - No established guidelines |
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease; Mulholland & Greenfield's Surgery 7e; Sabiston Textbook of Surgery; Harrison's Principles of Internal Medicine 22e
All little smaller table delete the management part
MEN Syndromes - Comparison Table
| Feature | MEN-1 (Werner Syndrome) | MEN-2A (Sipple Syndrome) | MEN-2B (MEN-3) | MEN-4 |
|---|---|---|---|---|
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant; ~50% de novo mutations | Autosomal dominant |
| Gene | MEN1 (TSG) - chr 11q13 | RET proto-oncogene - chr 10q11 | RET proto-oncogene - chr 10q11 | CDKN1B (TSG) |
| Protein | Menin - transcription factor complex component | RET receptor tyrosine kinase (binds GDNF) | RET receptor tyrosine kinase | p27 (Kip1) - CDK inhibitor |
| Mutation Type | Loss-of-function (two-hit model) | Gain-of-function (exons 10/11) | Gain-of-function (codon 918, tyrosine kinase domain) | Loss-of-function |
| Mechanism | Loss of menin → deregulated transcription → neoplasia | Constitutive RET activation → unchecked growth signaling | Constitutive RET activation (more potent than MEN-2A) | Loss of p27 → Rb phosphorylation uninhibited → unchecked cell cycle |
| Organs Involved | Parathyroid, Pancreas, Pituitary (3 Ps) | Thyroid (C-cells), Adrenal medulla, Parathyroid | Thyroid (C-cells), Adrenal medulla, Peripheral nervous system | Parathyroid, Pituitary, Pancreas (mimics MEN-1) |
| Age of Onset | 3rd-4th decade | 2nd-3rd decade | Childhood/infancy (earliest of all) | 5th decade (latest; milder) |
| Parathyroid | 80%-95% (first and most common manifestation); hyperplasia + adenomas; renal stones > bone disease | 10%-20%; multiglandular chief cell hyperplasia; usually asymptomatic | Absent (key difference from MEN-2A) | >90% (first manifestation); diffuse hyperplasia |
| Pancreas / GI | Leading cause of death; multifocal NETs - Gastrinoma (most common; duodenal wall) - Insulinoma (2nd most common) - VIPoma, glucagonoma (rare) | Not a feature | Not a feature | NETs in ~20%; gastrinoma most common type |
| Thyroid | Not a primary feature | MTC in ~100% of untreated patients; multifocal; bilateral; C-cell hyperplasia precedes; relatively indolent | MTC in ~100%; multifocal; bilateral; more aggressive than MEN-2A | Not a feature |
| Pituitary | 15%-50%; prolactinoma (most common); acromegaly (GH-secreting); rarely Cushing's | Not a feature | Not a feature | ~40%; ACTH-secreting adenoma more common (vs prolactinoma in MEN-1) |
| Adrenal | Adrenocortical adenomas (benign, non-functional) | Pheochromocytoma 40%-50%; bilateral in ~80%; benign (<10% malignant); adrenal medullary hyperplasia precedes | Pheochromocytoma; bilateral; benign; similar frequency to MEN-2A | Not a feature |
| Extra-endocrine Features | Lipomas; carcinoid tumors (thymic, bronchial); cutaneous angiofibromas; collagenomas | None | Mucosal neuromas (tongue, lips, eyelids); marfanoid habitus; ganglioneuromatosis of GI tract; thick lips; hypertrophied corneal nerves; constipation/megacolon picture; skeletal deformities (pectus, kyphosis, pes planus) | None |
| Key Clinical Features | Hypercalcemia; recurrent peptic ulcers (ZES); secretory diarrhea; hypoglycemia (insulinoma); galactorrhea/amenorrhea; acromegaly | Neck mass; hoarseness; episodic hypertension; headaches + diaphoresis + palpitations (pheo); renal stones; diarrhea (calcitonin excess) | Neck mass; mucosal neuromas on tongue/lips (often 1st sign in newborns); marfanoid habitus; pheo symptoms; GI dysmotility | Hypercalcemia; peptic ulcers; Cushing's disease or acromegaly |
| Key Biochemical Markers | Elevated PTH + Ca²⁺; fasting gastrin >1000 pg/mL; secretin stimulation test; fasting hypoglycemia + elevated insulin; elevated prolactin / IGF-1 | Elevated calcitonin (basal + stimulated); elevated plasma metanephrines; PTH + Ca²⁺ | Elevated calcitonin; elevated plasma metanephrines; RET mutation on genetic testing | PTH + Ca²⁺; fasting gastrin; prolactin; ACTH; IGF-1 |
| Screening | Annual Ca²⁺, PTH, gastrin, insulin, prolactin, IGF-1; MRI pituitary; CT/MRI abdomen; genetic testing of relatives from age 5-10 yrs | RET testing in all MTC patients (including sporadic); prophylactic thyroidectomy timing by mutation risk; annual calcitonin + metanephrines | RET genetic testing; thyroidectomy before 6 months of age; annual metanephrines; slit-lamp for corneal nerves | Next-gen sequencing for CDKN1B if MEN-1 negative; modified MEN-1 protocols (no consensus guidelines) |
| Complications | Metastatic pancreatic NETs (leading cause of death); nephrolithiasis; peptic ulcer bleeding/perforation; hypoglycemic coma; hypopituitarism; visual field defects | Metastatic MTC; hypertensive crisis from unrecognized pheochromocytoma; renal stones; Addisonian crisis post bilateral adrenalectomy | Metastatic MTC (early death if untreated); hypertensive crisis; GI pseudo-obstruction; skeletal deformities | Metastatic NETs; hypercalcemia complications; Cushing's disease sequelae |
| Prognosis | ~45% of deaths MEN-1 related; malignant NETs/carcinoids are the killers; hyperparathyroidism rarely fatal | Often indolent; prolonged survival even with metastatic MTC; pheo rarely malignant | Worst prognosis; most aggressive MEN; early death possible; small kindred size due to early mortality | Generally favorable; late and mild presentation; very rare (~80 cases in literature) |
| Key Distinguishing Points | - "3 Ps" mnemonic - Duodenum is #1 site for gastrinomas - TSG / loss-of-function - Pancreatic NETs are the killer | - Pheo MUST be excluded before thyroid surgery - Parathyroid involved (unlike MEN-2B) - RET gain-of-function | - No hyperparathyroidism - Mucosal neuromas + marfanoid habitus are pathognomonic - Most aggressive - De novo mutations common | - Phenocopies MEN-1 clinically - ACTH adenoma > prolactinoma - NETs less frequent - No established guidelines |
Sources: Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease; Mulholland & Greenfield's Surgery 7e; Sabiston Textbook of Surgery; Harrison's Principles of Internal Medicine 22e
Make it understandable by ug students
MEN Syndromes - Quick Reference for UG Students
Remember: All MEN syndromes are autosomal dominant, tumors are multifocal, occur at a younger age, and are more aggressive than sporadic tumors.
| Feature | MEN-1 | MEN-2A | MEN-2B | MEN-4 |
|---|---|---|---|---|
| Other Name | Werner Syndrome | Sipple Syndrome | Also called MEN-3 | - |
| Gene | MEN1 gene | RET gene | RET gene (different spot) | CDKN1B gene |
| Simple Explanation of Defect | "Brake" on cell growth is lost → uncontrolled growth | "Accelerator" of cell growth is stuck ON → uncontrolled growth | Same accelerator stuck ON, but harder than MEN-2A | Another "brake" is lost → looks like MEN-1 |
| Easy Mnemonic | 3 Ps - Parathyroid, Pancreas, Pituitary | Thyroid + Adrenal + Parathyroid | Thyroid + Adrenal + Neuromas (no parathyroid!) | Mimics MEN-1 |
| Parathyroid | ✅ Most common feature (80-95%); first to appear; causes high calcium → kidney stones | ✅ Mild, only 10-20% | ❌ ABSENT (important exam point!) | ✅ Most common feature (>90%); first to appear |
| Pancreas | ✅ Most dangerous; causes death - Gastrinoma → severe stomach ulcers (Zollinger-Ellison) - Insulinoma → low blood sugar attacks | ❌ Not involved | ❌ Not involved | ✅ Mild (only 20%); gastrinoma most common |
| Thyroid | ❌ Not involved | ✅ Medullary thyroid cancer in nearly 100%; appears in teens-20s; relatively slow | ✅ Medullary thyroid cancer in nearly 100%; appears in infancy/childhood; very aggressive | ❌ Not involved |
| Pituitary | ✅ 15-50%; usually prolactinoma (causes milk discharge, missed periods); rarely acromegaly | ❌ Not involved | ❌ Not involved | ✅ ~40%; ACTH-secreting tumor (causes Cushing's) more common here |
| Adrenal | ✅ Benign, harmless adrenal nodules | ✅ Pheochromocytoma (40-50%); usually both sides; causes high BP + headache + sweating | ✅ Pheochromocytoma; similar to MEN-2A | ❌ Not involved |
| Unique / Extra Features | Skin lipomas, carcinoid tumors, skin tags (angiofibromas) | Nothing extra beyond the 3 glands | ⭐ Lumps on tongue/lips (mucosal neuromas); Marfan-like body (tall, long limbs, flexible joints); GI constipation | Nothing extra |
| What Patient Looks Like | Middle-aged adult with kidney stones + stomach ulcers + hormonal issues | Young adult with neck lump + high BP episodes | Child/teen with bumps on tongue, thin body, Marfan appearance + neck lump | Middle-aged adult similar to MEN-1 |
| Most Important Blood Tests | High calcium; high gastrin; low blood sugar; high prolactin | High calcitonin; high plasma metanephrines | High calcitonin; high metanephrines | High calcium; high gastrin; high ACTH |
| Most Dangerous Complication | Spread of pancreatic tumors to liver = #1 cause of death | Medullary thyroid cancer spread | Medullary thyroid cancer (very aggressive, can kill in young age) | Spread of pancreatic tumors |
| Most Important Exam Point | Duodenum (not pancreas) is the #1 site for gastrinoma | Pheo must be operated on FIRST before thyroid surgery (or patient may die from BP crisis) | No parathyroid disease + mucosal neuromas = MEN-2B | Clinically same as MEN-1 but gene is different |
| Prognosis | Moderate; pancreatic cancers are the killers | Good; thyroid cancer is often slow | Worst of all; most aggressive; early death possible | Best; mildest and latest presentation |
Simple "What's Different" Summary
| MEN-1 vs MEN-2A | MEN-2A vs MEN-2B | |
|---|---|---|
| Key difference | MEN-1 has pancreas + pituitary; MEN-2A does NOT | MEN-2B has no parathyroid but has neuromas + marfanoid body |
| Gene | MEN-1 = MEN1 gene (brake); MEN-2A = RET gene (accelerator) | Both MEN-2A and 2B use RET gene, but different mutations |
Exam Favorites ⭐
- MEN-1 = 3 Ps (Parathyroid + Pancreas + Pituitary) → gene = MEN1 → protein = Menin
- MEN-2A = Medullary thyroid cancer + Pheo + Parathyroid → gene = RET
- MEN-2B = Medullary thyroid cancer + Pheo + Neuromas + Marfanoid (NO parathyroid) → gene = RET
- MEN-4 = Looks like MEN-1 → gene = CDKN1B → protein = p27
- In MEN-2, always check for pheo before operating on the thyroid
- MEN-2B is the most aggressive and the only one with physical deformities visible on the face/body
This is a shared conversation. Sign in to Orris to start your own chat.